You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Litigation Details for Purdue Pharma L.P. v. Teva Pharmaceuticals USA, Inc. (S.D.N.Y. 2014)

✉ Email this page to a colleague

« Back to Dashboard

Purdue Pharma L.P. v. Teva Pharmaceuticals USA, Inc. (S.D.N.Y. 2014)

Docket	⤷ Sign Up	Date Filed	2014-04-03
Court	District Court, S.D. New York	Date Terminated	2014-12-23
Cause	35:271 Patent Infringement	Assigned To
Jury Demand	None	Referred To
Patents	6,488,963; 7,674,799; 7,674,800; 7,683,072; 7,776,314; 8,114,383; 8,309,060; 8,337,888
Link to Docket	External link to docket

Small Molecule Drugs cited in Purdue Pharma L.P. v. Teva Pharmaceuticals USA, Inc.

The small molecule drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .

Details for Purdue Pharma L.P. v. Teva Pharmaceuticals USA, Inc. (S.D.N.Y. 2014)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2014-04-03	2		Code, for infringement of U.S. Patent No. 6,488,963 (the “’963 patent”). 2. By this aetion, Plaintiffs… series lof patent cases concerning United States Patent Nos. 7,674,799 (the “’799 patent”), 7,674,800…7,674,800 (the “’800 patent”), 7,683,072 (the “’072 patent”), 7,776,314 (the “’314 patent”), 8,114,383 (the “… “’383 patent”), 8,309,060 (the “’060 patent”), and 8,337,888 (the “’888 patent”). These cases were based…the ’963 patent was an act of infringement of the ’963 patent under the United States Patent Laws, 35	External link to document
2014-06-24	35		of U.S. Patent No. 6,488,963 (the "'963 Patent"). Those claim constructions of the '963 Patent shall apply…Court, this action shall be governed by the Local Patent Rules of the Southern District of New York. The… 23 December 2014 1:14-cv-02357 830 Patent None District Court, S.D. New York	External link to document
2014-11-06	69		familiar with the sole patent-in-suit, U.S. Patent No. 6,488,963 (“the ’963 patent”). Evidence on the invalidity…the ’963 patent is to make controlled release matrix dosage forms, as shown by the ’963 patent itself,… invalidity of the ’963 patent was admitted in Purdue v. Teva I ((11-cv-2400 (Impax); 11-cv-4694 (Sandoz…the issue of the alleged invalidity of the ’963 patent during the trial of Purdue v. Teva I, and that…Defenses”) relating to the invalidity of the ’963 patent identified below. With respect to infringement	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.